1219 PDF
1219 PDF
1219 PDF
2
agonist,
Antihistaminics
Cardiovascular
diseases
BP is at its lowest during
the sleep cycle and rises
steeply during the early
morning awakening
period
Nitroglycerin,
Calcium channel
blocker, ACE
inhibitors,
Blockers etc.
Arthritis Pain in the morning and
more pain at night
NSAIDs,
Glucocorticoids
Diabetes mellitus Increase in the blood
sugar level after meal
Sulfonylurea,
Insulin,
Biguanide
Attention deficit
syndrome
Increase in DOPA level in
afternoon
Methylphenidate
Hypercholesterolemia Cholesterol synthesis is
generally higher during
night than during day time
HMG CoA
reductase
inhibitors
MERITS
2
1.Predictable, reproducible and short gastric residence time.
2.Less inter- and intra-subject variability.
3.Improve bioavailability.
4.Limited risk of local irritation.
5.No risk of dose dumping.
6.Flexibility in design.
7.Improve stability.
LIMITATIONS OF PULSATILE DRUG DELIVERY
SYSTEM
22
1. Multiple manufacturing steps in case of Multiparticulate
drug delivery system.
2. Low drug load.
3. Incomplete release.
4. In vivo variability in single unit pulsatile drug delivery
system.
5. Drug dose manipulation in case of child and elder patients
is not possible.
6. Immediate withdrawal of drug is not possible.
RECENT ADVANCES IN THE PULSATILE DRUG
DELIVERY SYSTEM
Nowadays pulsatile drug delivery systems are gaining
importance in various disease conditions specifically in
diabetes where dose is required at different time intervals.
Among these systems, multi-particulate systems (e.g. pellets)
offer various advantages over single unit which include no
risk of dose dumping, flexibility of blending units with
different release patterns, as well as short and reproducible
gastric residence time
23
. Multiparticulate systems consists
pellets of different release profile which can be of any type
like time dependent, pH dependent, micro flora activated
system as discussed in the previous sections. Site and time
specific oral drug delivery have recently been of great interest
in pharmaceutical field to achieve improved therapeutic
efficacy. Gastroretentive drug delivery system is an approach
to prolong gastric residence time, thereby targeting
sitespecific drug release in upper gastrointestinal (GI) tract.
Floating drug delivery system (FDDS) and bioadhesive drug
delivery are widely used techniques for gastro retention. Low
density porous multiparticulate systems have been used by
researchers for formulation of FDDS. Sharma and Pawar
developed multiparticulate floating pulsatile drug delivery
system using porous calcium silicate and sodium alginate for
time and site specific drug release of meloxicam
24
. Various
pulsatile technologies have been developed on the basis of
methodologies as discussed previously. These includes
OROS technology, CODAS technology, CEFORM
technology, DIFFUCAPS technology, Three-dimensional
printing, timerx etc.
Table 2. Marketed technologies of pulsatile drug delivery
Technology Mechanism Proprietoy name
and dosage form
API Disease Reference
CODAS
Multiparticular pH
dependent system
Verelan
PM; XL
release capsule
Verapamil HCL Hypertension 25
DIFFUCAPS
; XL
Tablets
Verapamil
HCL,Propranolol HCL
Hypertension 26
Three dimen-
Externally
TheirForm
Externally regulated
system
TheirForm